SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
on which registered
|(Nasdaq Global Select Market)|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On August 3, 2021, Singular Genomics Systems, Inc. (the “Company”) issued a press release, which, among other matters, sets forth the Company’s results of operations for the second fiscal quarter ended June 30, 2021. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The foregoing information, including Exhibit 99.1, is being furnished under Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
|99.1||Press Release, dated August 3, 2021.|
|104||Cover Page Interactive Data File (embedded within XBRL document).|
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 3, 2021
|Singular Genomics Systems, Inc.|
Senior Vice President, Finance
Principal Financial Officer and Principal Accounting Officer
Singular Genomics Systems, Inc. Announces Second Quarter Financial Results and Operations Update
La Jolla, CA, August 3, 2021 Singular Genomics Systems, Inc., a company focused on delivering genomic technologies for the advancement of science and medicine, today reported its second quarter 2021 financial results and highlighted recent operating and corporate achievements. Investors and the general public are invited to view the companys quarterly report, filed today on Form 10-Q with the Securities and Exchange Commission (www.sec.gov).
We are on track to take orders for the G4 integrated sequencing solution by year end and to ship commercial systems by mid-year 2022. said Chairman and CEO Drew Spaventa. In preparation for that launch, we are optimizing the system performance, setting up manufacturing operations, building out the commercial team and forming partnerships to validate and implement our breakthrough integrated sequencing platform. The team has executed well across financial, infrastructure, development and other key timelines.
Recent Operating and Corporate Highlights
Initial public offering Closed an upsized offering of common stock, including the underwriters over-allotment, resulting in gross proceeds, before fees, of approximately $258.1 million and a cash, cash equivalents and short-term investments balance of $371.7 million at June 30, 2021.
Beta sites - Initiated and completed key beta system placements and validation activities at a genomics research organization and a clinical stage biopharma company, providing the first external performance metrics validation of the G4 Integrated Solution.
Early access program Initiated an early access program including initial partner/site identification and contracts. Partnering will extend through commercial launch and is expected to allow key partners and market influencers to gain access, while providing valuable feedback prior to full commercial launch.
Commercial team build out Hired Scott Thomas (former VP of Global Commercial Strategy at Illumina) as SVP of Sales and Marketing. Thomas joins genomics industry veteran David Daly (former CEO at Thrive Earlier Detection and former CCO at Foundation Medicine) in building a world-class commercial team designed to deliver an elite standard of customer service, support and partnering.
Facilities/Manufacturing Executed a lease agreement and commenced buildout of a dedicated manufacturing facility to support the launch and anticipated demand for both the G4 and PX Integrated Solutions.
Select summary financial results are provided below. For detailed results of the second quarter and first half of 2021, please refer to the companys results filed with the Securities and Exchange Commission or via the investor section of the companys website (www.singulargenomics.com).
Operating expenses for the second quarter of 2021 totaled $13.9 million, compared to $6.8 million for the second quarter of 2020.
Operating expenses for the second quarter of 2021 included non-cash stock-based compensation of $2.3 million.
Net loss for the second quarter of 2021 was $37.5 million, compared to $6.8 million for the second quarter of 2020.
Other income (expense) for the second quarter of 2021 included $23.8 million non-cash, non-recurring expense associated with the change in fair value of convertible promissory notes that converted into common stock at the IPO.
Cash, cash equivalents and short-term investments, excluding restricted cash, at June 30, 2021 totaled $371.7 million, compared to $26.9 million at December 31, 2020.
Selected Financial Information
($-amounts in thousands, except per share data)
|Three Months Ended
Selected Statement of Operations Items:
Total operating expenses*
Loss from operations
Basic and diluted net loss per share
Weighted-average shares used to compute basic and diluted net loss per share
|June 30,||December 31,|
Selected Balance Sheet Items:
Cash, cash equivalents, and short-term investments
Accounts payable and accrued expenses
Total stockholders equity (deficit)
Operating expenses for the second quarter of 2021 included non-cash stock-based compensation of $2.3 million.
Other income (expense) for the second quarter of 2021 included $23.8 million non-cash, non-recurring expense associated with the change in fair value of convertible promissory notes that converted into common stock at the time of the IPO.
About Singular Genomics Systems, Inc.
Singular Genomics is a life science technology company that is leveraging novel, next generation sequencing (NGS) and multiomics technologies to build products that empower researchers and clinicians. Our mission is to accelerate genomics for the advancement of science and medicine. Our Singular Sequencing Engine is the foundational platform technology that forms the basis of our products
in development as well as our core product tenets: accuracy, speed, flexibility and scale. We are currently developing two integrated solutions that are purpose built to target applications in which these core product tenets matter most. Our first integrated solution, the G4 Integrated Solution, is targeted at the NGS market. Our second integrated solution in development, the PX Integrated Solution, combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument to offer a versatile multiomics solution. The G4 and PX Integrated Solutions are both comprised of an instrument and an associated menu of consumable kits.
Certain statements contained in this press release, other than historical information, constitute forward-looking statements within the meaning of the Federal securities laws. Forward-looking statements include, but are not limited to, statements regarding: (i) our ability to successfully complete the development of our G4 and PX Integrated Solutions; (ii) our ability to meet our commercial launch and product delivery timelines and objectives; and (iii) our ability to achieve customer and scientific acceptance for our G4 and PX Integrated Solutions. Any such forward-looking statements are based on our managements current expectations and are subject to a number of risks and uncertainties that could cause our actual future results to differ materially from our managements current expectations or those implied by the forward-looking statements. These risks and uncertainties include, but are not limited to: (i) we have incurred significant losses since inception, we expect to incur significant losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability; (ii) we have no history commercializing our products or technology; (iii) the life sciences technology market is highly competitive, and if we fail to compete effectively, our business and operating results will suffer; (iv) if we are sued for infringing, misappropriating or otherwise violating intellectual property rights of third parties, this litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates; (v) if our products fail to achieve early customer and scientific acceptance, we may not be able to achieve broader market acceptance for our products, and our revenues and prospects may be harmed; and (vi) the COVID-19 pandemic and efforts to reduce its spread have adversely impacted, and are expected to continue to materially and adversely impact, our business and operations. These and other risk factors that may affect our future results of operations are identified and described in more detail in our filings with the SEC, including our Quarterly Report on Form 10-Q for period ended June 30, 2021, filed with the SEC on August 3, 2021. Accordingly, you should not rely upon forward-looking statements as predictions of future events or our future performance. Except as required by applicable law, we undertake no obligation to update publicly or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Dan Budwick, 1AB